You are viewing the site in preview mode

Skip to main content


Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Fig. 3

Comparison of objective response in select trials. Legend: Figure presenting a comparison of objective response in study participants, expressed in percent individuals, with different treatment regimens in CheckMate 012, NCT02000947 and CheckMate 067 trials. Abbreviations: NIVO, nivolumab; IPI, ipilimumab; DURVA, durvalumab; TREME, tremelimumab; Q(x)W, every (x) weeks; NSCLC, non-small cell lung cancer

Back to article page